Compare KBSX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | SNTI |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | Taiwan | United States |
| Employees | 394 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 53.6M |
| IPO Year | N/A | N/A |
| Metric | KBSX | SNTI |
|---|---|---|
| Price | $1.38 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 7.6K | ★ 4.1M |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,890,395.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.46 | N/A |
| 52 Week Low | $1.26 | $1.26 |
| 52 Week High | $15.48 | $5.96 |
| Indicator | KBSX | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 34.90 |
| Support Level | $1.31 | $1.34 |
| Resistance Level | $1.60 | $2.88 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 21.15 | 6.36 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.